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Available online 9 August 2016Eosinophils account for 1–3% of peripheral blood leukocytes and accumulate at sites of allergic inﬂammation,
where they play a pathogenic role. Studies have shown that treatmentwithmepolizumab (an anti-IL-5monoclo-
nal antibody) is beneﬁcial to patientswith severe eosinophilic asthma, however, themechanism of precisely how
eosinophils mediate these pathogenic effects is uncertain. Eosinophils contain several cationic granule proteins,
including Eosinophil Peroxidase (EPO). The main signiﬁcance of this work is the discovery of EPO as a novel li-
gand for the HER2 receptor. Following HER2 activation, EPO induces activation of FAK and subsequent activation
of β1-integrin, via inside-out signaling. This complex results in downstream activation of ERK1/2 and a sustained
up regulation of bothMUC4 and the HER2 receptor. These data identify a receptor for one of the eosinophil gran-
ule proteins and demonstrate a potential explanation of the proliferative effects of eosinophils.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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MUC41. Introduction
Eosinophils accumulate at local inﬂammatory sites in allergic condi-
tions such as asthma and allergic rhinitis [1–3], where they interactwith
resident cells including epithelial and nerve cells [4–7]. IL-5 is a keyme-
diator of eosinophil proliferation and activation, and studies have
shown that treatment with mepolizumab and other anti-IL-5 monoclo-
nal antibodies reduces the number of blood and sputumeosinophils [8],
reduces exacerbations and improves quality of life in patients with re-
fractory eosinophilic asthma [9,10]. Eosinophils are also implicated in
the pathogenesis of disease states such as inﬂammatory bowel disease
[11], rhinitis [12,13], helminth infections [14] and certain epithelial can-
cers [15] and play a role in non-pathological proliferative conditions
such as normal mammary gland development [16]. Hence, eosinophils
are implicated in the pathogenesis of a wide variety of human condi-
tions. A suggested link between these pathological and physiological
conditions is that eosinophilsmay play a role in regeneration and repair,
although the contribution of the individual granule proteins to these
processes is undeﬁned [17]., RCSI Education and Research
. This is an open access article underEosinophils contain four cationic granule proteins MBP, EDN, ECP
and EPO, all of which are toxic at high concentrations to epithelial, mus-
cle and neural cells as well as certain micro-organisms and parasites.
However, at non-cytotoxic concentrations, eosinophil cationic proteins
have been implicated in cell and tissue remodeling [18]. Other than a
neural muscarinic receptor, no receptor that maymediate cell signaling
has been identiﬁed for any of the eosinophil granule proteins [19].
Previous work in our laboratory, carried out in the neuroblastoma cell
line IMR32, showed that EPO induced phosphorylation of HER2 at the
Y1248 autophosphorylation site, and this led to loss of the cyclin-
dependent kinase p27kip from the nucleus and upregulation of the cell
proliferation marker Ki67 [20]. These data suggest that EPO may be a li-
gand for HER2. The HER family consists of heavily glycosylated, single-
chain modular cell surface glycoproteins [21,22]. There are four structur-
ally related familymemberswhich interactwith each other; HER1 (EGFR/
ErbB1), HER2 (neu/ErbB2), HER3 (ErbB3) and HER4. HER2 overexpres-
sion is notably associated with several human cancers, particularly breast
and ovarian [23–25]. There is no known ligand for HER2, which acts as a
co-receptor, formingheterodimerswith other EGFR familymembers [26],
whereas HER1, HER3 and HER4 are associated with one or more speciﬁc
ligands [21]. MUC4, however, functions as a tethered endogenous HER2
ligand and inﬂuencesHER2 activation [27–29]. In this studywe examinedthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Primers.
Primer Sequence Melting temperature
HER2 forward 5′-CAG CAG AGG ATG GAA CAC AG-3′ 59.4
HER2 reverse 5′-ACT CCT GGA TAT TGG CAC TG-3′ 57.3
MUC4 forward 5′-CTG TGT CTC TGC CTC CTT CC-3′ 61.4
MUC4 reverse 5′-TTG TTG AGC CTG TTG AGG TG-3′ 57.3
β-actin forward 5′-GGA CTT CGA GCA AGA GAT GG-3′ 59.4
β-actin reverse 5′-AGG AAG GAA GGC TGG AAG AG-3′ 59.4
2 K. Hennigan et al. / Clinical Immunology 171 (2016) 1–11the effect of EPO on human bronchial airway epithelial cells. We hypoth-
esized, that EPO interacts with and activates the HER2 receptor with en-
gagement and activation of the β1-integrin and then to downstream
signaling events important for cell function, including inducing expres-
sion of the HER2 and MUC4 complex.
2. Materials and methods
2.1. Cell culture
Normal human bronchial epithelial 16HBE14o cells were maintained
in MEM plus 10% FCS and 100 U/ml penicillin/streptomycin (GIBCO
Invitrogen) and plated in the same medium but without FCS for experi-
mentation. In some experiments cells were pre-treated with inhibitors,
namely: AG825 (Calbiochem/Merck Biosciences) (10 μM, 2 h, inhibitor
of HER2 activation), anti-CD29 (BD Biosciences) (1 μg/ml, 2 h β1 integrin
inhibitor), PF573228 (TOCRIS Bioscience) (3 μM, 1 h, FAK inhibitor), or
PNGase F (2 U/ml, 3 h, enzyme that catalyzes the complete removal of
N-linked oligosaccharide chains from glycoproteins. Some cells were
treated with EPO (4 μg/ml) or MBP(4 μg/ml) for various times.
2.2. Isolation of EPO and MBP
Eosinophil granule proteinswere isolated from eosinophils of patients
withmarked eosinophilia as previously described [30,31]. Brieﬂy, sequen-
tial acid extractions were performed using 0.01 M HCl with extracts 1–3
containing N80% of EPO. Extracts were then fractionated (1 ml fractions)
on a Sephadex G-50 column. Absorbance at 280 nm revealed distinct
peaks for EPO (fractions 36–50) and MBP (fractions 74–87). Fractions
were further proﬁled by SDS-PAGE with Coomassie staining to conﬁrm
the homogeneity of each preparation.
2.3. Surface Plasmon resonance (SPR)
Surface Plasmon resonance (SPR) analysis was performed using a
Biacore® 3000 and data analysis was carried out using BIAevaluation
4.1 software™. Analysis was carried out with research grade CM5 sen-
sor chips using ﬁltered degassed HBS-EP+ pH 7.4 (0.01 M HEPES,
0.15 M NaCl, 3 mM EDTA and 0.005% Tween-20®) as a running and
sample buffer. All Biacore related consumables were purchased from
GE Healthcare, Sweden. Chip Preparation: A research CM5 chip (GE
Healthcare, UK) was prepared by immobilization of 7.5 μg/ml EPO in
10 mM sodium acetate, pH 4.2 using EDC-NHS coupling chemistry and
1 M ethylenediamine to cap unreacted sites [32] resulting in a chip
preparation of 10,000RU of EPO. Buffer screening: Initially, the optimal
binding buffers were examined to examine the interaction of recombi-
nant HER2 and EPO. rHER2 (e-bioscience, UK) was reconstituted inmo-
lecular grade water (1 mg/ml) and was then prepared in a number of
buffer compositions of varying NaCl, without EDTA or Tween-20, and
also in standard HBS-EP+. To assess binding, the samples were injected
for 3min at 30 μl/min, dissociationmonitored for 5min and regenerated
with a 30 s pulse of 5 mM NaOH. The data was collected and evaluated
using the BIAevaluation 4.1 software package. Binding Analysis: HER2
(e-bioscience, UK) was reconstituted in 1× HBS-EP+ (1 mg/ml) and
was injected randomly at a number of concentrations (37.50, 18.75,
9.38, 4.99 and 0 nM), over the immobilized EPO for 3 min (ﬂow rate
30 μl/min) and dissociation was monitored for 10 min. Regeneration
of the surface was carried out as previously described. The data from
the reference ﬂow cell was subtracted to remove any systematic arte-
facts and each antigen response was then double-referenced by
subtracting the buffer response (zero analyte concentration).
2.4. mRNA analysis
Total RNA was isolated from the cells with TRI reagent™ (Sigma)
and reverse transcribed using QuantiTect Reverse Transcription cDNAsynthesis kit (Qiagen, Hilden, Germany), according to the manufac-
turers' instructions. Quantitative RT-PCR analysis was carried out on
the LightCyclerTM 1.0 (Roche) using QuantiTect SYBR Green PCR kit
(Qiagen), according to themanufacturers' instructions as previously de-
scribed [33]. Primers were speciﬁc to HER2,MUC4 or β-actin as normal-
izing gene (Table 1; Euroﬁns). Expression levels for each gene were
quantiﬁed against serial dilutions of puriﬁed PCR product.
2.5. Protein preparation
Protein lysates were extracted in Relax buffer (100 mM KCl, 3 mM
NaCl, 3.5 mM MgCl2, 10 mM HEPES, pH 7.4) containing protease and
phosphatase inhibitor cocktails (Roche Diagnostics, Mannheim,
Germany) and 1× Triton. Lysates were disrupted bymotorized pestle be-
fore nuclei were removed by centrifugation (1000g for 10min) [34]. Pro-
tein concentration was established by the Bradford method [35].
2.6. SiRNA transfection
16HBE14o cells were serum-starved overnight prior to transfection
with silencing RNA (30 nM ﬁnal concentration) against HER2, FAK,
GAPDH or a non-speciﬁc negative control silencing RNA (siRNA) (Ap-
plied Biosystems) in serum-free conditions, using Transfast (Promega)
according to the manufacturers' instructions. Controls lacking siRNA
were also set up. Down-regulation of the target genes was conﬁrmed
by Western blotting.
2.7. Western blotting
Protein (20, 30 or 65 μg, see individualﬁgure legends)was subjected
to SDS-PAGE electrophoresis and transferred overnight in Transfer buff-
er (150 mM Glycine, 20 mM Tris, 10%SDS, 2% Methanol) to nitrocellu-
lose for Western blotting. Membranes were incubated in blocking
buffer, (1×-Tris-buffered saline containing 5% skimmed milk powder
(Fluka) and 0.1% (v/v) Tween-20), for 1 h at room temperature then
blocking buffer containing 1:200 dilution of primary antibody FAK,
pFAK or pERK, or 1:500 dilution of anti-active β1-integrin primary anti-
body (Millipore, CA) or ERK2 (Santa Cruz; Santa Cruz, CA, USA) or 1×-
Tris-buffered saline containing 5% bovine serum albumin (Sigma) and
0.1% (v/v) Tween-20 containing 1:1000 dilution phospho-Y1248-
HER2 or HER2 primary antibody (Cell Signaling Technology; Danvers,
MA, USA), overnight at 4 °C with gentle rotation. After 6 times 5 min
washes (Tris-buffered saline containing 0.1% (v/v) Tween-20), mem-
branes were incubated for 2 h at room temperature in blocking buffer
containing appropriate HRP-conjugated secondary antibody (Santa
Cruz; 1:2000 dilution). After 6 times 5 min washes, membranes were
exposed to Luminol Chemiluminescent reagent (Santa Cruz) for 1 min
at room temperature followed by X-OMAT light sensitive ﬁlm to obtain
an image.
2.8. Immunoﬂuorescence
16HBE14o cells were cultured on sterile coverslips, treated and ﬁxed
with 3.7% paraformaldehyde for 10 min at room temperature. Cells
were incubated in blocking buffer (5% normal goat serum in 1×-PBS,
0.5% v/v Triton) for 1 h at room temperature. Cells were washed 3
3K. Hennigan et al. / Clinical Immunology 171 (2016) 1–11times for 5 min in PBS between blocking, primary and secondary anti-
body incubations. Primary and secondary antibodies were diluted in
blocking buffer (without Triton); anti-β1-integrin (JB1B) (Santa Cruz
Biotech) 1:80 or mouse IgG (goat anti-mouse IgG – Texas Red) (Santa
Cruz Biotech) 1:200. Phalloidin (Alexa 488) (Invitrogen) 1:1000 and
Mouse IgG (Sigma) 1:80. Both primary and secondary antibody incuba-
tionswere for 1 h at room temperature. Nuclear stainingwas carried out
during mounting with VECTASHIELD Hard Set Mounting medium with
DAPI (Vector Laboratories, Inc.). Images were obtained using an
LSM710 Confocal Microscope (Zeiss Inc. UK).
2.9. Bioinformatic analysis
The EPO protein sequence (accession number P11678) was divided
using a 10 residue sliding window into 706 peptides which were sub-
mitted to the PepSite webserver [36], with the PDB structure for
HER2, 1N8Z [37], chain C. Five peptides were predicted to bind to
HER2 (pb 0.05), all containing the peptide KLQPQR. The six residuepep-
tide KLQPQR was predicted to interact with 1N8Z residues TYR C 252
and PHE C 257 (p b 0.05).
2.10. Statistical analysis
Values are expressed as mean ± SEM. Data was evaluated by two-
tail Student's t-test or by ANOVA using the Graphpad Instat program.
A p value of 0.05 or less was taken as signiﬁcant.
3. Results
3.1. EPO is a ligand for HER2
A recombinant form of the extracellular domain of HER2 (amino
acids 23–652) was employed for SPR studies (rHER2, e-bioscience UK)
to ascertain if EPO is a ligand for HER2. Due to its extremely positive
charge, EPO (pI = 10.8) could not be orientated as the analyte and so
was immobilized on the chip surface. The buffer composition, to mini-
mize non-speciﬁc interactions, was examined and demonstrated that
the interaction was inﬂuenced by NaCl concentrations above 300 mM
(Fig. 1A) suggesting that the charge component of the proteins was a
critical part of the binding process (in HBS pH 7.4). Varying the buffer
pH reduced non-speciﬁc interaction between rHER2 and the reference
ﬂow cell (at rHER2 theoretical pI of 6.2) however, the binding curves
took on a biphasic appearance. Reliable data was obtainable in HBS-
EP+ (Fig. 1B)whichminimized non-speciﬁc rHER2 interactions. Despite
immobilizing various densities of EPO, the surface activitywas relatively
low which prevented rigorous analysis (densities at 4000, 8000 and
12,000 RU were examined). Binding analysis demonstrated a concen-
tration dependent interaction between the rHER2 and EPO (Fig. 1C).
As the extracellular domain of HER2 is known to be sufﬁcient for
ligand-independent homodimerization [38], this was expected to play
a role in the interaction and consequently the data was ﬁtted with the
bivalent model for kinetic characterization. The derived binding con-
stants suggested afﬁnity ka1 = 1.29 × 105 M−1 s−1, kd1 =
2.03 × 10−3 s−1 and ka2 = 6.15 × 10−4 RU−1, kd2 = 5.15 × 10−4 s−1.
To further examine the nature of the rHER2-EPO interaction, the
monoclonal antibody to HER2, Herceptin, was used to shed light on
the region of rHER2 involved in EPO binding. In competitive binding as-
says, aﬁxed rHER2 concentration incubatedwith excess of Herceptin (5,
50 and 500-fold) did not disrupt the interaction of EPO and HER2 and
suggested that Herceptin and EPO do not share a common binding re-
gion (Fig. 2A). This was further examined by allowing rHER2 to bind
EPO and subsequently, injecting Herceptin which showed small levels
of binding, which could be attributed to lower rHER2 capture levels,
and further implies non-overlapping binding sites (Fig. 2B).
Bioinformatic analysis with PepSite was used to predict potential
polypeptide interactions between EPO and HER2. Only one speciﬁcregion of the EPO amino acid sequence (KLQPQR, amino acids 103 to
108) reported a signiﬁcant binding prediction for the extracellular do-
main of HER2 (p = 0.01726). The predicted interacting residues on
the HER2 receptor structure are TYR 252 and PHE 257. As shown in
the binding model in Fig. 2C, this predicted binding location for EPO is
distinct from the knownHerceptin binding location onHER2, consistent
with experimental results.
3.2. Enzymatic removal of N-linked oligosaccharide chains prevents EPO-
induced activation of HER2
In functional studies, EPO (4 μg/ml) induced a rapid and sustained
phosphorylation of the HER2 receptor (Fig. 3A). Prior studies have
shown that N-linked glycosylation (NLG) is a critical step in the post
translational modiﬁcation of RTKs including HER2 [39,40]. Hence,
16HBE14o cells were pretreated with an enzyme that catalyzes the
complete removal of N-linked oligosaccharide chains from glycopro-
teins (PNGase F, 2 U/ml, 3 h) and then exposed to EPO for varying
times. These studies showed that there was no longer an induction in
the phosphorylation of HER2 (Fig. 3B). EPO induced an upregulation
of total HER2 receptor expression at a protein level (Fig. 3C). The in-
creased phosphorylation of HER2 by EPO is not due simply to the in-
crease in overall HER2 levels as the EPO-induced increase in
phosphorylated HER2 occurs as early as 10 min (Fig. 3A), whereas a
similar EPO-induced upregulation of the HER2 receptor, only occurs at
4 h (Fig. 3C). EPO had no effect on the transcriptional expression of
HER1 or MUC1 at any timepoint (data not shown). MBP, another eosin-
ophil cationic protein isolated by similarmethodology to EPO, had noef-
fect on levels of total or phosphorylated HER2, indicating the speciﬁcity
of the HER2 response to the eosinophil granule protein EPO (Fig. 3D).
3.3. EPO induces a HER2-dependent activation of β1-integrin
To determine if EPO-induced HER2 activation had further conse-
quences for bronchial epithelial cells, we examined β1-integrin activa-
tion in response to EPO treatment. Confocal microscopy showed that,
compared to untreated cells, EPO (4 μg/ml) induced the activation of
β1-integrin (red staining) at 4 h and 18 h (Fig. 4A). These results were
conﬁrmed by Western Blotting using an antibody speciﬁc to the active
form of β1-integrin (Fig. 4B). Pre-treatment with a neutralizing anti-
body to β1-integrin, (anti-CD29, 1 μg/ml, 2 h) (Fig. 4C) conﬁrmed that
the clusters observed in Fig. 4A were β1-integrin. EPO-induced integrin
activation is mediated via HER2, since pre-treatment with AG825
(chemical inhibitor of the tyrosine kinase activity of HER2) prevented
activation of β1-integrin observed by confocal ﬂuorescence imaging
and Western blot (Fig. 4D and E).
3.4. EPO-induced FAK and ERK activation
The downstream signaling consequences of EPO-induced HER2 acti-
vationwere then investigated.Western Blotting showed that EPO (4 μg/
ml) induced the phosphorylation of FAK in a time-dependent manner
from as early as 10 min (Fig. 5A). This EPO-induced FAK activation
was inhibited by AG825 indicating its dependence on the initial activa-
tion of HER2. In further support of this, silencing RNA against HER2 re-
duced the levels of phosphorylated FAK and also activated β1-integrin
under EPO-treated conditions (Fig. 5B). The EPO induced FAKphosphor-
ylation was also reduced by PNGase F pre-treatment (Fig. 5A).
Silencing RNA directly targeted against FAK did not impact EPO-
induced HER2 expression (Fig. 5C). However, silencing RNA against ei-
ther FAK or HER2 reduced phospho ERK expression under EPO treated
conditions, indicating that ERK activation is a downstream target of
this pathway (Fig. 5C). Indeed, EPO treatment (4 μg/ml) was shown to
induce the phosphorylation of ERK1/2 in a time-dependent manner
from as early as 10 min and this was inhibited by both AG825 and
300nM NaCl
500nM NaCl
800nM NaCl
Fig. 1. Analysis of the interaction between EPO and rHER2 on Biacore The analysis was carried out on immobilized EPO. (A) Double reference subtracted binding of 75 nM rHER2 to EPOwas
performed over a range of salt concentrations (300–800 mM). The binding of rHER2 was diminished between 300 and 500 mM NaCl suggesting the importance of charge for the
interaction. The overlay box shows an expansion of each sample. In (B) the binding proﬁle for rHER2 in HBS-EP+ is shown. The red trace is the 75 nm rHER2 and the blue trace 0 nM
(buffer only) raw data (online reference cell subtracted). The black trace is the double reference subtracted data (75 nM rHER2 minus 0 nM response). (C) Kinetic analysis of three
HER2 concentrations (double reference subtracted data shown) is ﬁtted with a bivalent analyte model (black line) with local Rmax ﬁtting. The kinetic evaluation suggested ka1 =
1.29 × 105 M−1 s−1, kd1 = 2.03 × 10−3 s−1.
4 K. Hennigan et al. / Clinical Immunology 171 (2016) 1–11
CHer2 (200nM)
Her2 (200nM) with Herceptin (1µM)
Her2 (200nM) with Herceptin (10µM)
Her2 (200nM) with Herceptin (100µM)
50µM Herceptin
0µM Herceptin
50µM Herceptin Reference Subtracted (0µM)
i ii iii
A
B
Fig. 2. Assessment of interaction of EPO-rHER2 and Herceptin (A) Competitive binding proﬁles for EPO to rHER2 with incubation for 1 h with an excess of Herceptin. No diminishment of
binding for EPO was observed in comparison to rHER2 with zero Herceptin. The overlay box shows an expansion of each sample. (B) Sequential injection of rHER2 across EPO
(i) followed by Herceptin (ii) and monitoring of dissociation for 5 min (iii). The red trace is the dissociation of rHER2 from EPO (with no Herceptin) and the blue trace is the data
collected after injection of Herceptin (50 μM). The black trace is the double referenced data (removing the dissociation of rHER2 from EPO). The overlay box is an expansion showing
that Herceptin bound to rHER2 despite the receptor interacting with EPO. The results suggest that the binding site for EPO does not overlap with the known binding site for Herceptin
(amino acid region 557–603 [37]). (C) 3D crystal structure of HER2-Herceptin complex with predicted binding site for EPO indicated. Blue and grey: extracellular domain of HER2
with grey indicating the amino acids closest to the transmembrane domain. Green and yellow: heavy and light chains of Herceptin antibody. Red: Amino acids of EPO which are
predicted to interact with HER2. Magenta: HER2 amino acid 252. Cyan: HER2 amino acid 257.
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Fig. 3. EPO induces HER2 phosphorylation in an N-linked glycosylation-dependent mechanism (A) 16HBE14o cells were exposed to EPO (4 μg/ml) for varying times and fold change in pHER2
(at its autophosphorylation site Y1248) was assessed by Western blotting. (B) 16HBE14o cells were ﬁrst pretreated with an enzyme that catalyzes the complete removal of N-linked
oligosaccharide chains from glycoproteins (PNGase F, 2 U/ml, 1 h) and then exposed to EPO (4 μg/ml) for varying times. Fold change in pHER2 was assessed. (C) 16HBE14o cells were
exposed to EPO (4 μg/ml) for varying times and fold change in HER2 was assessed by Western blotting. The graphs show the fold change in pHER2 (A,B) or HER2 (C) expression levels
in response to EPO treatment compared to untreated cells in the absence (A,C) or presence (B) of PNGase F at the indicated times. (n = 3, mean ± sem; *p b 0.05, **p b 0.01,
***p b 0.001). (D) 16HBE14o cells were exposed to MBP (4 μg/ml) for varying times and expression of pHER2 and HER2 was assessed by Western blotting. Images are representative
of n = 3 experiments.
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EPO-induced activation of HER2 (Fig. 6).
3.5. EPO regulates the transcriptional levels of HER2 and MUC4
EPO (4 μg/ml) induces an increase in transcriptional expression
of HER2. This was mediated via the initial activation of the HER2 re-
ceptor since EPO-induced HER2 upregulation was inhibited whencells were pre-treated with AG825 (10 μM, 2 h) (Fig. 7A). MUC4 is
a tethered ligand for HER2 inﬂuencing its activation [27]. Real-
time PCR showed that EPO induced an upregulation in the tran-
scriptional expression of MUC4 (Fig. 7B). Furthermore, in the pres-
ence of AG825, the levels of MUC4 did not increase in response to
EPO treatment (Fig. 7B), indicating that EPO-induced upregulation
in MUC4 gene expression was dependent on the initial activation of
the HER2 receptor.
Fig. 4. EPO induces a pHER2-dependent activation of β1 integrin (A, D) 16HBE14o cells were grown on coverslips and treated with EPO (4 μg/ml) for various times or left untreated (as
indicated). Some wells were pre-treated with a speciﬁc anti-β1-integrin neutralizing antibody (anti-CD29, 1 μg/ml, 2 h) or pretreated with a HER2 tyrosine kinase inhibitor (AG825,
10 μM, 2 h), as indicated on images. β1-integrin (red) was stained with a mouse integrin-β1 antibody (JB1B, Santa Cruz) and a Texas Red goat anti-mouse IgG secondary antibody. β1-
integrin activation is indicated by clustering and co-localization with F-actin ﬁbers, stained with Phalloidin (green), resulting in the orange clusters visible at 18 h EPO treatment (A).
In (B) cells were treated with EPO (4 μg/ml) for varying time points, cellular protein was subjected to Western blot analysis and probed for active β1-integrin and against ERK2 for
normalization. In (C) cells were ﬁrst pre-treated with anti-CD29 (1 μg/ml, 2 h) and then exposed to EPO (4 μg/ml) for varying time points. Cellular protein was subjected to Western
blot analysis and probed for active β1-integrin and against ERK2 for normalization. In (D) confocal microscopy images show the comparison of cells treated with EPO for 18 h in the
absence or presence of AG825 (as indicated). β1-integrin (red) activation is indicated by clustering and co-localization with F-actin ﬁbers. In (E) 16HBE14o cells were ﬁrst pre-treated
with AG825 (10 μM, 2 h) and then exposed to EPO (4 μg/ml) for varying time points. The graphs show the fold change in active β1-integrin expression levels in response to EPO
treatment compared to untreated cells in the absence (B) or presence (C, E) of inhibitors at the indicated times. (n = 3, mean ± sem; **p b 0.01, ***p b 0.001).
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In this studywehavedemonstrated that the eosinophil granule protein
EPO is a ligand for theHER2 receptor. EPOengagesHER2via a site separate
to that bound by the receptor inhibitor Herceptin and potentially via
amino acids 252 and 257 of HER2. Ligand binding of EPO to HER2 results
inphosphorylationof theHER2 receptorwith subsequentphosphorylation
of the scaffold protein, FAK and inside-out activation of β1-integrin. To-
gether this complex of HER2, FAK and β1-integrin leads to activation of
the MAP kinase ERK1/2 with a subsequent increase in HER2 receptor
and MUC4 mRNA expression (Fig. 8). These data imply a mechanism for
the recognized proliferative and remodeling effects of EPO [41].This study was designed to investigate how eosinophil granule pro-
teins interactwith cells. To date a vast amount of data has been reported
on how eosinophils accumulate at speciﬁc sites of inﬂammation [42]
and there is important historic evidence of a non-speciﬁc charge-
mediated toxicity by these proteins [43,44]. In our prior work, we and
others have shown that at even higher concentrations than studied
here, of up to 10 microgram/ml (1–3 log order lower than those that
are toxic) the granule proteins MBP1 and EPO prevent cell necrosis
and apoptosis [45,46] via differentmechanisms, indicating that the con-
centrationswe used in these experiments are not toxic to these cells. In-
deed, both granule proteins induce quite separate intracellular signaling
pathways with different cellular consequences [20,47]. However, there
AB C
siRNA:        Neg Neg HER2
+EPO (4ug/ml)
HER2
Active B1 integrin
pFAK
Total FAK
Beta actin
Fig. 5. EPO induces the activation of focal adhesion kinase (FAK) and HER2 which are required for activation of β1 integrin (A) Western blots of 16HBE14o protein from cells treated with or
without EPO (4 μg/ml) at the indicated times. Somewere pre-treatedwith the inhibitor AG825 (10 μM, 2 h) or the endoglycosidase PNGase F (2 U/ml, 1 h) (see legend) and probedwith a
rabbit anti-human pFAK antibody. The graphs show the fold change in pFAK expression levels in response to EPO treatment compared to untreated cells in the absence or presence of
inhibitors at the indicated times. (n = 3, mean ± sem; *p b 0.05, **p b 0.01, ***p b 0.001). The blots shown are representative of 3 similar experiments. Protein levels of total FAK
remain unchanged in the presence of EPO and the various inhibitors studied (data not shown). (B) Western blots of 16HBE14o cells grown in the absence or presence of EPO (4 μg/ml,
18 h) as indicated. Cells were transfected with silencing RNA (siRNA) to a scrambled negative control (Neg) or HER2. (C) Western blots of 16HBE14o cells grown in the absence or
presence of EPO (4 μg/ml, 18 h) as indicated. Cells were transfected or not with siRNA to a scrambled negative control (Neg), HER2, FAK or GAPDH. Table shows the fold change in
HER2 and FAK protein expression following transfection.
8 K. Hennigan et al. / Clinical Immunology 171 (2016) 1–11has been little insight into the speciﬁc cellular receptors for these gran-
ule proteins, and this investigation is the focus of this work.
We investigated the interaction of EPO and HER2 using SPR. This,
in vitro, technique facilitated investigation of the binding and the rela-
tive strength of that binding to the HER2 receptor and we used inhibi-
tors which have known binding sites, to investigate the possible sites
of interaction of EPOwith HER2. EPO interactedwith the HER2 receptor,
and the strength of the interaction was calculated using a bivalent ana-
lytemodel. It is worth noting that the high charge of the interaction pair
was a barrier to examination of the interaction in a 1:1 fashion (withEPO as the analyte). To further investigate the nature of the interaction,
Herceptin's ability to inhibit the interaction was examined. Herceptin is
known to interact with three regions of HER2, which are towards the C-
terminus (amino acids 557–561, 570–573 and 593–603) [37]. From the
analysis, we concluded that the interaction of EPO was unaffected by
Herceptin binding suggesting that EPO binds within a different region
of HER2. This ﬁnding is further supported by mathematical modelling
which predicts the most likely interaction between EPO peptide se-
quence and the 3D structure of HER2 is at amino acids 252 and 257 of
HER2.
pERK 
ERK2 
Fig. 6. EPO induces the activation of extracellular signal-regulated kinase (ERK) via N-linked glycosylation through the initial activation of HER2Western blots of 16HBE14o protein from cells
treatedwith orwithout EPO (4 μg/ml) at the indicated times. Somewere pre-treatedwith the inhibitor AG825 (10 μM, 2 h) or the endoglycosidase PNGase F (2 U/ml, 1 h) (see legend) and
probed with a rabbit anti-human pERK antibody. The graphs show the fold change in pERK expression levels in response to EPO treatment compared to untreated cells in the absence or
presence of inhibitors at the indicated times. (n=3,mean±sem; *pb 0.05, **p b 0.01, ***pb 0.001). The blots shownare representative of 3 similar experiments. Protein levels of total ERK
remain unchanged in the presence of EPO and the various inhibitors studied (data not shown).
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autophosphorylation site Y1248, a critical site of tyrosine kinase activity
[48]. EPO also increased the levels of expression of the HER2 receptor in
a manner that was dependent on the initial phosphorylation of the re-
ceptor, suggesting that this may be a pro-proliferative effect of EPO.
The increased phosphorylation of HER2 by EPO is not due simply to
the increase in overall HER2 levels as the EPO-induced increase in phos-
phorylated HER2 occurs as early as 10 min, whereas a similar EPO-
induced upregulation of the HER2 receptor only occurs at 4 h. Prior
work has shown that N-linked glycosylation (NLG) is needed for properFig. 7. EPO induces a pHER2-dependent increase in the transcriptional levels of HER2 and
MUC4 16HBE14o cells were treated with EPO (4 μg/ml) in the absence of or following
pre-treatment with AG825 (10 μM, 2 h). Cellular material was harvested for RNA
isolation and cDNA synthesis and Real-time PCR was performed. Graphs show the fold
change in HER2 (A) or MUC4 (B) relative to β-actin expression in response to EPO
(4 μg/ml) at the indicated time points compared with untreated cells (n = 3, mean ±
sem; *p b 0.05, **p b 0.01, ***p b 0.001).membrane insertion, ligand binding and receptor functioning of HER2.
All observed effects of EPO were inhibited by the endoglycosidase,
PNGase F [49].
Integrins can facilitate growth factor-mediated activation of ERK
[50] and FAK (whose pathway is activated by integrins and growth fac-
tor receptors) and is linked to signaling pathways that modify the cyto-
skeleton and activate mitogen-activated protein kinase (MAPK)
cascades. Integrin clustering and association with the cytoskeleton ap-
pears to give rise to integrin-growth factor receptor complexes [50,
51]. The interactions and interdependence of growth factor receptors
such as the HER family and integrins are underscored by observations
such thatβ1-integrin can facilitate bypassing of the anti-proliferative ef-
fects of the HER2 neutralizing antibody, trastuzumab, in breast cancer
cells [52]. In the current experiments EPO also activated β1-integrin, al-
beit indirectly, via pHER2-mediated activation of FAK. We found,
through the use of silencing RNA experiments that when HER2 is si-
lenced, the activation of β1-integrin is reduced. While we recognize
the limitations of using one single time-point for this data and agree
that it does not fully complete the argument, in the context of the rest
of this work, it is supportive. The formation of this scaffold is important
for activation of β1-integrin, for interaction with the HER2 receptor and
potentially for activation of further downstreamsignalingmolecules, for
example ERKMAP Kinase signaling. The EPO-induced activation of both
FAK and ERK was also dependent on NLG.
Further downstream, we have shown that EPO induces an increase
in the transcriptional expression of the HER2 receptor as well as
mucin gene MUC4. EPO-induced upregulation of MUC4 and HER2 is of
particular interest. MUC4 is a high-molecular weight glycoprotein that
has been implicated in cancer progression particularly due to its cell sig-
naling and anti-adhesive properties. MUC4 also interacts with HER2 by
stabilizing the HER2 receptor and through activation of certain HER2
domains.MUC4 andHER2 interactions are of importance in theprogres-
sion of a variety of epithelial tumors including breast cancer and pancre-
atic cancers, where eosinophils, in particular EPO are also a feature [27].
The main signiﬁcance of this work is the discovery of EPO as a novel
ligand for theHER2 receptor. The activation of theHER2 receptor by EPO
is interesting because both EPO andHER2 are upregulated in certain dis-
ease states. For example, HER2 is associatedwith particularly aggressive
forms of breast cancer [53] and pancreatic cancer [54]. Because eosino-
phils are implicated in chronic pancreatitis [55], one can speculate that
chronic eosinophil activation in tissues may contribute to the develop-
ment of malignancy. EPO, by activating HER2 and subsequent ERK acti-
vation may contribute to cell and tissue repair and also to cell
proliferation which may mediate effects on mucous production. Thus,
Fig. 8. Summary diagram EPO binds to the HER2 receptor, resulting in its activation, which in turn activates FAK. FAK acts as a scaffold protein bringing together β1-integrin and the HER2
receptor with subsequent HER2-dependent, FAK-dependent β1-integrin activation. EPO also induces a pHER2-dependent, FAK-dependent activation of ERK 1/2.
10 K. Hennigan et al. / Clinical Immunology 171 (2016) 1–11this is a rationale to investigate inhibitors of these pathways, when eo-
sinophil tissue presence is prolonged or in conditions where eosinophil
concentrations are elevated. Such studies could potentially allow us to
provide intervention treatment before EPO tips the balance from
being helpful to becoming pathological.
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